EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long‐term follow‐up of bulky classic Hodgkin lymphoma managed with ABVD and PET‐guided RT demonstrates excellent outcomes in PET‐negative cases

J L Kim iD, D Villa iD, R P Tonseth, A S Gerrie iD, D Wilson, F Benard, C P Venner, B Skinnider, P Farinha, G W Slack, A C Lo iD, D W Scott und 2 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.19859 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von J L Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Hodgkin Disease, Antineoplastic Combined Chemotherapy Protocols, Positron-Emission Tomography. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The outcome of 221 patients with bulky (≥10 cm) classic Hodgkin lymphoma (cHL) treated with doxorubicin, bleomycin, vinblastine, dacarbazine and consolidative radiotherapy (RT) only in those with a positive end‐of‐treatment (EOT) positron emission tomography (PET) scan was evaluated. With a median follow‐up of 9.6 years, 5‐ and 10‐year progression‐free survival (PFS) in EOT PET‐negative cases were 94.0% and 90.4%, respectively, and in PET‐positive cases, 5/10‐year PFS was 64.6% ( p < 0.001), with 15% overall receiving RT. Five‐year PFS for Deauville (D) score DX/D1–3 was 93.6%, compared with D4 66.7% ( p < 0.001) and D5 33.3% ( p < 0.001). Omission of RT in EOT PET‐negative cases is associated with excellent long‐term outcomes in bulky cHL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseAntineoplastic Combined Chemotherapy ProtocolsPositron-Emission TomographyHumansBleomycinVinblastineMaleDoxorubicinFemaleAdultMiddle AgedDacarbazineFollow-Up StudiesAgedAdolescentYoung AdultTreatment Outcome

Stichwörter der Autor:innen

ABVDPET‐adapted RTbulky Hodgkin lymphomaconsolidative RT

Substanzen

BleomycinVinblastineDoxorubicinDacarbazine

Autor:innen und Institutionen

  • Division of Hematology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Centre for Lymphoid Cancer and Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Molecular Imaging and Therapy Program, Vancouver, British Columbia, Canada.
  • Centre for Lymphoid Cancer and Department of Pathology, BC Cancer, Vancouver, British Columbia, Canada.
  • Department of Radiation Oncology, BC Cancer, Vancouver, British Columbia, Canada.

ORCID-Profile: J L Kim, D Villa, A S Gerrie, A C Lo, K J Savage

Zitieren

APA

Kim, J. L., Villa, D., Tonseth, R. P., Gerrie, A. S., Wilson, D., Benard, F., Venner, C. P., Skinnider, B., Farinha, P., Slack, G. W., Lo, A. C., Scott, D. W., Sehn, L. H., & Savage, K. J. (2025). Long‐term follow‐up of bulky classic Hodgkin lymphoma managed with ABVD and PET‐guided RT demonstrates excellent outcomes in PET‐negative cases. British Journal of Haematology. https://doi.org/10.1111/bjh.19859

Vancouver

Kim JL, Villa D, Tonseth RP, Gerrie AS, Wilson D, Benard F, et al. Long‐term follow‐up of bulky classic Hodgkin lymphoma managed with ABVD and PET‐guided RT demonstrates excellent outcomes in PET‐negative cases. British Journal of Haematology. 2025. doi:10.1111/bjh.19859

BibTeX
@article{Kim2025,
  author = {Kim, J L and Villa, D and Tonseth, R P and Gerrie, A S and Wilson, D and Benard, F and Venner, C P and Skinnider, B and Farinha, P and Slack, G W and Lo, A C and Scott, D W and Sehn, L H and Savage, K J},
  title = {Long‐term follow‐up of bulky classic Hodgkin lymphoma managed with ABVD and PET‐guided RT demonstrates excellent outcomes in PET‐negative cases},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.19859}
}
Kostenlos starten →